VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. His experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development. For more details, see the full press release here.
The appointment comes as VERAXA aims to accelerate its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody-based therapeutics. The company’s BiTAC platform is designed to target solid tumors, a challenging area in oncology where few effective treatments exist. Erkel’s leadership is expected to drive the platform from preclinical stages into clinical development, potentially offering new options for patients with hard-to-treat cancers.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company’s approach combines rigorous quality-by-design principles with transformative technologies to rapidly advance its pipeline. BiTAC is a registered trademark of VERAXA Biotech GmbH.
Investors and stakeholders can find the latest news and updates relating to VRXA in the company’s newsroom at https://ibn.fm/VRXA. The company also notes that certain statements in this article are forward-looking and subject to risks and uncertainties, as detailed in its SEC filings, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Erkel’s appointment signals a strategic move to strengthen VERAXA’s scientific leadership at a critical juncture as the company seeks to transition from research to clinical-stage development. With his extensive background in T-cell engagers and antibody engineering, Erkel is well-positioned to oversee the progression of BiTAC candidates, which could address significant unmet medical needs in solid tumor oncology. The transition period with outgoing CSO Rick Austin ensures continuity while Erkel takes the helm.
